Skip to main content
. Author manuscript; available in PMC: 2011 Oct 12.
Published in final edited form as: Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006690. doi: 10.1002/14651858.CD006690.pub2
Methods Parallel randomised controlled trial

Participants SETTING: Inpatients and outpatients at Liyuan Hospital, China
WHO PARTCIPATED: 62 people (32 in intervention group, M/F 17/15, mean age 65.3
yrs, mean disease duration 3.1yrs, mean weight 82.3kg; 30 in control group, M/F
15/15, mean age 66.1 yrs, mean disease duration 3.6yrs, mean weight 82.1kg)
INCLUSION CRITERIA: IGT according to WHO,1998
EXCLUSION CRITERIA: none reported
CO-MORBIDITIES: none reported
CO-MEDICATIONS: none reported

Interventions INTERVENTION: Fufang cangzhu decoction (cang zhu 15g, yi yi ren 24g, sang shen
20g, shan yao 30g, huang bai 10g, li zhi hue 20g, di long 10g) oral, decoction, 150ml,
bid
CONTROL: metformin 0.25g, oral, tablet, tid

Outcomes FBG (mmol/L), 1hr-GTT (mmol/L), 2hr-GTT (mmol/L), weight (kg), waist-hip ratio
(WHR), triglycerides (mmol/L), total cholesterol (mmol/L), fasting insulin (mU/L)
All outcomes measured at baseline and at trial completion (8 weeks).

Study details DURATION OF INTERVENTION: 8 weeks
DURATION OF FOLLOW-UP: 8 weeks
RUN-IN PERIOD: none

Publication details LANGUAGE OF PUBLICATION: Chinese
COMMERCIAL FUNDING: no
NON-COMMERCIAL FUNDING: no
PUBLICATION STATUS (PEER REVIEW JOURNAL): yes
PUBLICATION STATUS (JOURNAL SUPPLEMENT): no
PUBLICATION STATUS (ABSTRACT): yes

Stated aim of study Quote “To observe therapeutic effect of Fufang Cangzhu Decoction on senile obesity
or overweight with impaired glucose tolerance (IGT)”.

Notes

Risk of bias table